FUTURE DIRECTIONS

The rapid progression of cancer genomics in recent years has significantly influenced clinical cancer care. Deep sequencing has unraveled the complexities of clonal heterogeneity, shedding light on acquired resistance mechanisms. The concept of blood-based monitoring through liquid biopsy has emerged as a sensitive and cost-effective proxy for tumor response, addressing challenges in obtaining recurrent tumor biopsy materials. Immunogenomics, driven by genomic studies, has transformed the landscape of cancer immunotherapy. The correlation between high mutational loads and positive responses to checkpoint blockade therapy has challenged traditional definitions of actionable mutations. The potential use of immunotherapies as a second-line approach following DNA-damaging chemotherapy opens new avenues for treatment.

Genomics-driven efforts to identify tumor-specific neoantigens for personalized vaccine development showcase the potential of the field. Despite the progress, cancer remains a formidable challenge, and ongoing clinical and translational efforts in cancer genomics promise continued impact. The interplay between genomics, liquid biopsy, and immunogenomics holds the key to advancing personalized and effective cancer treatments. As research unfolds, the results are anticipated with excitement, offering hope for further breakthroughs in cancer medicine.